US Patent

US9539262 — Ophthalmic composition comprising a prostaglandin

Method of Use · Assigned to Sun Pharma Advanced Research Co Ltd · Expires 2028-10-15 · 2y remaining

Vulnerability score 75/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects a pharmaceutical composition for ophthalmic use that includes one or more prostaglandin derivatives or salts and a stabilizing amount of polyethylene glycol hydroxystearate.

USPTO Abstract

The present invention relates to a pharmaceutical composition suitable for ophthalmic use comprising one or more prostaglandin derivatives or salts, a stabilizing amount of polyethylene glycol hydroxystearate and pharmaceutically acceptable vehicle.

Drugs covered by this patent

Xalatan (LATANOPROST) · Thea Pharma

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-2400`	—	Xalatan

Patent Metadata

Patent number: US9539262
Jurisdiction: US
Classification: Method of Use
Expires: 2028-10-15
Drug substance claim: No
Drug product claim: No
Assignee: Sun Pharma Advanced Research Co Ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.